Galanakis Dennis K, Neerman-Arbez Marguerite, Scheiner Tomas, Henschen Agnes, Hubbs Doris, Nagaswami Chandrasekaran, Weisel John W
Blood Bank, L5, University Hospital, HSC, SUNY, Stony Brook, New York 11794-7530, USA.
Blood Coagul Fibrinolysis. 2007 Dec;18(8):731-7. doi: 10.1097/MBC.0b013e3282f10157.
We detail for the first time the uniquely altered fibrin polymerization of homophenotypic Aalpha R16H dysfibrinogen. By polymerase chain reaction amplification and DNA sequencing, our new proposita's genotype consisted of a G>A transition encoding for Aalpha R16H, and an 11 kb Aalpha gene deletion. High-performance liquid chromatography disclosed fibrinopeptide A release approximately six times slower than its fibrinopeptide B. Turbidimetric analyses revealed unimpaired fibrin repolymerization, and abnormal thrombin-induced polymerization (1-7 mumol/l fibrinogen, > 96% coagulable), consisting of a prolonged lag time, slow rate, and abnormal clot turbidity maxima, all varying with thrombin concentration. For example, at 0.2-3 U/ml, the resulting turbidity maxima ranged from lower to higher than normal control values. By scanning electron microscopy, clots formed by 0.3 and 3 thrombin U/ml displayed mean fibril diameters 42 and 254% of the respective control values (n = 400). Virtually no such differences from control values were demonstrable, however, when clots formed in the presence of high ionic strength (micro = 0.30) or of monoclonal antibeta(15-42)IgG. The latter also prolonged the thrombin clotting time approximately three-fold. Additionally, thrombin-induced clots displayed decreased elastic moduli, with G' values of clots induced by 0.3, 0.7 and 3 thrombin U/ml corresponding to 11, 34, and 45% of control values. The results are consistent with increased des-BB fibrin monomer generation preceding and during polymerization. This limited the inherent gelation delay, decreased the clot stiffness, and enabled a progressively coarser, rather than finer, network induced by increasing thrombin concentrations. We hypothesize that during normal polymerization these constitutive des-BB fibrin monomer properties attenuate their des-AA fibrin counterparts.
我们首次详细描述了同型表型Aα R16H异常纤维蛋白原独特的纤维蛋白聚合改变。通过聚合酶链反应扩增和DNA测序,我们新确诊患者的基因型包括编码Aα R16H的G>A转换以及11 kb的Aα基因缺失。高效液相色谱显示纤维蛋白肽A的释放速度比其纤维蛋白肽B慢约6倍。比浊分析显示纤维蛋白再聚合未受损害,但凝血酶诱导的聚合异常(纤维蛋白原浓度为1 - 7 μmol/L,可凝固性>96%),表现为延迟时间延长、速率缓慢以及异常的凝块浊度最大值,所有这些均随凝血酶浓度而变化。例如,在0.2 - 3 U/ml时,产生的浊度最大值范围从低于到高于正常对照值。通过扫描电子显微镜观察,0.3和3 U/ml凝血酶形成的凝块显示平均纤维直径分别为各自对照值的42%和254%(n = 400)。然而,当在高离子强度(μ = 0.30)或单克隆抗β(15 - 42)IgG存在下形成凝块时,与对照值几乎没有这种差异。后者还使凝血酶凝血时间延长约三倍。此外,凝血酶诱导的凝块显示弹性模量降低,0.3、0.7和3 U/ml凝血酶诱导的凝块的G'值分别相当于对照值的11%、34%和45%。这些结果与聚合前和聚合过程中des - BB纤维蛋白单体生成增加一致。这限制了固有的凝胶化延迟,降低了凝块硬度,并使得随着凝血酶浓度增加诱导形成的网络逐渐变粗而非变细。我们推测在正常聚合过程中,这些组成性的des - BB纤维蛋白单体特性会减弱其des - AA纤维蛋白对应物的特性。